RecruitingPhase 2NCT06093061

Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma

Studying Nasopharyngeal carcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Cancer Centre, Singapore
Principal Investigator
Melvin LK CHUA, MBBS, FRCR, PhD, FAMS
National Cancer Centre, Singapore
Intervention
CCRT with Maintenance Tislelizumab and Metronomic Capecitabine(combination_product)
Enrollment
69 target
Eligibility
21-99 years · All sexes
Timeline
20242029

Study locations (2)

Collaborators

BeiGene · Tan Tock Seng Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06093061 on ClinicalTrials.gov

Other trials for Nasopharyngeal carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Nasopharyngeal carcinoma

← Back to all trials